FDC vs FCT: Rosuvastatin + Ezetimibe

In Real-World Practice (Бельгия & Франция)
Study Design
TOTAL SAMPLE
N = 15,643
Treatment Episodes
FDC GROUP (1 PILL) N = 11,300 💊
FCT GROUP (2 PILLS) N = 4,343 💊💊
FDC: Fixed-Dose Combination | FCT: Free-Combination Therapy
Adherence & Persistence (Main Data)

A. PERSISTENCE (Duration)

MEDIAN TIME TO DISCONTINUATION
FDC
200 days
FCT
142 days
48%
FDC at 1 Year
27%
FCT at 1 Year
HR = 0.54
FDC patients are 46% less likely to stop treatment.

B. ADHERENCE (PDC ≥ 80%)

ODDS RATIO (OR)
= 3.00
3x
HIGHER CHANCES
of adherence with
ONE PILL
Clinical Results (LDL-C & MACE)
🩸

A. LDL-C REDUCTION

How Adherence Affects LDL-C
  • PERSISTENT PATIENTS:
    10% GREATER REDUCTION
  • ADHERENT PATIENTS:
    9.6% GREATER REDUCTION
❤️

B. CV EVENTS (MACE)

Exploratory Analysis

RISK OF MACE: HR = 0.60

40% LOWER RISK in FDC Group

*Note: Main analysis did not find significant difference due to low event numbers.

Conclusions
SUMMARY: ONE PILL (FDC) instead of TWO is associated with BETTER ADHERENCE, LONGER PERSISTENCE, and MORE SIGNIFICANT LDL-C REDUCTION.